CN1413589A - Composition of paeoniflorin and albiflorin and its preparation method - Google Patents
Composition of paeoniflorin and albiflorin and its preparation method Download PDFInfo
- Publication number
- CN1413589A CN1413589A CN 02133298 CN02133298A CN1413589A CN 1413589 A CN1413589 A CN 1413589A CN 02133298 CN02133298 CN 02133298 CN 02133298 A CN02133298 A CN 02133298A CN 1413589 A CN1413589 A CN 1413589A
- Authority
- CN
- China
- Prior art keywords
- radix paeoniae
- peoniflorin
- lactone glucoside
- composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
A composition of paeoniflorin and albiflorin is prepared from peony through extracting in water to obtain aqueous solution, resin adsorption, alcohol eluting, concentrating, and chromatography by alumina column and silica gel column. It can be used to prepare to medicines in different forms.
Description
Technical field:
The present invention relates to medical technical field, exactly it is the composition and method of making the same of peoniflorin and lactone glucoside of Radix Paeoniae.
Background technology:
Radix Paeoniae is the dry root of Ranunculaceae Radix Paeoniae subfamily Paeonia herbaceos perennial.The so-called Radix Paeoniae Alba and Radix Paeoniae Rubra (Paeonia lactifora Pall, P.veitchii Lynch and P.obovataMaxim), can think that according to the record in applicable cases and the successive dynasties book on Chinese herbal medicine now the Radix Paeoniae Alba is the root of the Radix Paeoniae plant of cultivation, Radix Paeoniae Rubra is then mainly from the root of wild Radix Paeoniae.
Radix Paeoniae cold nature, bitter in the mouth acid, the function that nourishing blood to suppress the hyperactive liver is arranged, delay middle pain relieving, hold back bright receipts antiperspirant." herbal classic " record: " main pathogen stomachache is removed bloody sputum, and is broken hard long-pending, cold and heat hernia abdominal mass, pain relieving diuresis, will and spirit." China's breast abdomen waist rib pain, spontaneous sweating, fever due to yin deficiency, menoxenia, metrorrhagia, leukorrhagia of being used for the treatment of among the people.Modern pharmacological research shows that Radix Paeoniae has analgesia, calmness, spasmolytic, protects the liver, blood vessel dilating, antiinflammatory, immunomodulating, improve effects such as learning and memory behavior, and monoterpenes chemical compounds such as peoniflorin are the main matter bases of these physiologically actives.Peoniflorin (paeoniflorin) was got from Radix Paeoniae first in 1963, separated again afterwards and obtained Hydroxy peoniflorin (Oxypaeoniflorin), lactone glucoside of Radix Paeoniae (Albiflorin), benzoylpaeoniflorin (Benzoylpaeoniflorin), acetyl peoniflorin (acetylpaeoniflorin) and galloylpaeoniflorin chemical compounds such as (galloylpaeoniflorin) [" time precious traditional Chinese medical science traditional Chinese medicines " 1999,10 (7): 544].
In recent years, many researchs about Paeonia plant peony glycosides assay are arranged, paeoniflorin content has a very big-difference in wild and the cultivation Radix Paeoniae between the different places of production and position.For formulating practicable quality control standard, result of study shows: paeoniflorin content is bordering on or a little more than root, withered middle content is not low yet in the Radix Paeoniae rhizome, illustrates that single index still is not enough to control its quality; Paeoniflorin content generally is higher than the cultivation product in the wild product Radix Paeoniae Rubra, show 3% greatly and be demarcation line [" CHINA JOURNAL OF CHINESE MATERIA MEDICA " 2000,25 (12): 714], nineteen ninety-five version " content of paeoniflorin is not less than 2% in the own Radix Paeoniae Rubra of Chinese pharmacopoeia standard code, and content of paeoniflorin also can reach in the general Radix Paeoniae Alba.
At present, Radix Paeoniae Alba extract is not also had unified standard, the Radix Paeoniae Alba total glucosides capsule on the market is the preparation of being made by the effective site of extracting in the Chinese medicine Radix Paeoniae Alba, has pharmacological actions such as antiinflammatory and immunomodulating, is used for the treatment of rheumatoid arthritis clinically.Bibliographical information [" PLA's Acta Pharmaceutica Sinica " 2002,18 (2): 107] is arranged: adopt HPLC with the content (see the following form) of contained peoniflorin in the Radix Paeoniae Alba as quantitative chemical index determining Radix Paeoniae Alba total glucosides, content of paeoniflorin all is lower than 40%.
Content of paeoniflorin mensuration in the Radix Paeoniae Alba total glucosides capsule (mg/0.3g, n=3)
Lot number content (mg) percentage composition (%)
990417 110 36.6
990611 108 36.0
990906 106 35.3
Annotate: the Radix Paeoniae Alba total glucosides capsule 's content is every 0.3g Radix Paeoniae Alba total glucosides extract.
Summary of the invention:
The composition and method of making the same that the purpose of this invention is to provide a kind of peoniflorin and lactone glucoside of Radix Paeoniae, and the medical usage of the compositions of clear and definite peoniflorin and lactone glucoside of Radix Paeoniae.It comprises peoniflorin and lactone glucoside of Radix Paeoniae, it is characterized in that: the content of peoniflorin and lactone glucoside of Radix Paeoniae sum is higher than 90% in the described compositions, and the ratio of peoniflorin and lactone glucoside of Radix Paeoniae is 7: 3～9: 1.Described compositions can be made folk prescription and compound medicinal formulation.Described pharmaceutical preparation can be made into slow release or controlled-release pharmaceutical formulation.Described pharmaceutical preparation can be made into coelenteron administration, spray delivery, Transdermal absorption or oral pharmaceutical preparation.Described pharmaceutical preparation can be made into ejection preparation or infusion preparation.Described compositions can be used for substituting Radix Paeoniae Alba extract or Radix Paeoniae Alba total glycosides and other medicines (containing Chinese medicine extract or active component) and forms compound medicinal formulation.The preparation method of said composition mainly is made up of following processing step: 1, dry Radix Paeoniae root (Ranunculaceae Paeonia plant) is cut into decoction pieces and gets the water extract behind water extraction; 2,, get eluent with the ethanol water elution after removing water-solubility impurity by reverse adsorbent resin; 3, eluent is through concentrating, and concentrate must be rich in peoniflorin and lactone glucoside of Radix Paeoniae component with alumina column chromatography; 4, will be rich in peoniflorin and lactone glucoside of Radix Paeoniae component in 3 after silica gel column chromatography obtains compositions.
Advantage of the present invention is: we are main components through secular peoniflorin and the lactone glucoside of Radix Paeoniae of experimental studies have found that, can be by specific technical process, markization contains the compositions of peoniflorin and lactone glucoside of Radix Paeoniae component, and the proportion control in said composition is 7: 3～9: 1 scope with peoniflorin and lactone glucoside of Radix Paeoniae, thereby provides reliable material base for the standardization and the modernization of Radix Paeoniae single preparations of ephedrine and compound preparation.
Description of drawings:
Fig. 1 detects figure for the present invention by HPLC.
Fig. 2 separates peak 1 component warp for two components among the present invention through preparation HPLC
1H-NMR figure.
Fig. 3 is peak 1 a component warp among Fig. 1
1H-NMR and
13C-NMR figure.
Fig. 4 is peak 2 component warps among Fig. 1
1H-NMR figure.
Fig. 5 is peak 2 component warps among Fig. 1
1H-NMR and
13C-NMR figure.
Indication compositions technical descriptioon of the present invention:
1. described compositions detects (post: ODS 4.6 * 250mm by HPLC; Wavelength: 230nm; Mobile phase: methanol: water (38: 62) provides two peaks (Fig. 1), and peak 1 (6.5min) is lactone glucoside of Radix Paeoniae (albiflorin), and peak 2 (8.1min) is peoniflorin (paeoniflorin).
2. two components are separated peak 1 component structure warp through preparation HPLC in the described compositions
1H-NMR (Fig. 2) and
13C-NMR (Fig. 3) confirms as lactone glucoside of Radix Paeoniae; Peak 2 component structure warps
1H-NMR (Fig. 4) and
13C-NMR (Fig. 5) confirms as peoniflorin [4].
3. described composition component assay
Peoniflorin and the lactone glucoside of Radix Paeoniae total content in described compositions
Lot number amount of composition (mg) content (mg) percentage composition (%)
010813 101.0 97.0 96.0
010819 104.9 102.2 97.3
010907 98.2 96.1 98.1
010914 101.8 97.2 95.3
The specific embodiment:
Embodiment 1:
Dry Radix Paeoniae medical material section 10Kg, extract 2 times with water boil, each 2 hours, pass through reverse adsorption resin column behind the extracting liquid filtering, reuse alcohol water elution, eluent concentrates the back and uses alumina column chromatography, must be rich in peoniflorin and lactone glucoside of Radix Paeoniae component, after silica gel column chromatography obtains the described compositions of this patent (hereinafter to be referred as this compositions) 150g.
Embodiment 2:
This compositions 50g mixes with microcrystalline Cellulose 45g and magnesium stearate 5g, and mixture is used for beating sheet, every heavy 0.2g, and every contains this compositions 0.1g.In conjunction with symptom, obey the 1-2 sheet, every day 2-3 time at every turn.
Embodiment 3:
This compositions 50g with corn starch 50g, adds water and makes soft material, crosses 12 mesh sieve pelletizes, and drying makes granule, incapsulates, and the heavy 0.2g of every capsules content contains this compositions 0.1g.In conjunction with symptom, obey the 1-2 sheet, every day 2-3 time at every turn.
Embodiment 4:
This compositions 5g ploughs pure 20g with dextran-40 or mountain and phosphoric acid buffer mixes in right amount, is used for the water for injection dissolving, by the general operation process of injection, makes every 5ml of injection, contains this compositions 0.05g.In conjunction with symptom, prop up with 1-4 at every turn, mix use, every day 1 time with transfusions such as injecting sodium chloride.
Embodiment 5:
This compositions 5g ploughs pure 20g with dextran-40 or mountain and phosphoric acid buffer mixes in right amount, is used for the water for injection dissolving, by the general operation process of injection, and fill, lyophilizing is made every of freeze dried injection and is contained this compositions 0.05g.In conjunction with symptom, prop up with 1-4 at every turn, mix use, every day 1 time with transfusions such as injecting sodium chloride.Claim is not limited to institute and gives an actual example.
Claims (7)
1, the composition and method of making the same of peoniflorin and lactone glucoside of Radix Paeoniae, it comprises peoniflorin and lactone glucoside of Radix Paeoniae, it is characterized in that: the content of peoniflorin and lactone glucoside of Radix Paeoniae sum is higher than 90% in the described compositions, and the ratio of peoniflorin and lactone glucoside of Radix Paeoniae is 7: 3～9: 1.
2, the composition and method of making the same of peoniflorin according to claim 1 and lactone glucoside of Radix Paeoniae is characterized in that: described compositions can be made folk prescription and compound medicinal formulation.
3, the composition and method of making the same of peoniflorin according to claim 2 and lactone glucoside of Radix Paeoniae is characterized in that: described pharmaceutical preparation can be made into slow release or controlled-release pharmaceutical formulation.
4, the composition and method of making the same of peoniflorin according to claim 2 and lactone glucoside of Radix Paeoniae is characterized in that: described pharmaceutical preparation can be made into coelenteron administration, spray delivery, Transdermal absorption or oral pharmaceutical preparation.
5, the composition and method of making the same of peoniflorin according to claim 2 and lactone glucoside of Radix Paeoniae is characterized in that: described pharmaceutical preparation can be made into ejection preparation or infusion preparation.
6, the composition and method of making the same of peoniflorin according to claim 2 and lactone glucoside of Radix Paeoniae is characterized in that: described compositions can be used for substituting Radix Paeoniae Alba extract or Radix Paeoniae Alba total glycosides and other medicines (containing Chinese medicine extract or active component) and forms compound medicinal formulation.
7, the preparation of compositions method of a kind of peoniflorin as claimed in claim 1 and lactone glucoside of Radix Paeoniae, it is characterized in that: the preparation method of said composition mainly is made up of following processing step: 1, dry Radix Paeoniae root (Ranunculaceae Paeonia plant) is cut into decoction pieces and gets the water extract behind water extraction; 2,, get eluent with the ethanol water elution after removing water-solubility impurity by reverse adsorbent resin; 3, eluent is through concentrating, and concentrate must be rich in peoniflorin and lactone glucoside of Radix Paeoniae component with alumina column chromatography; 4, will be rich in peoniflorin and lactone glucoside of Radix Paeoniae component in 3 after silica gel column chromatography obtains compositions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021332983A CN1314403C (en) | 2002-10-29 | 2002-10-29 | Composition of paeoniflorin and albiflorin and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021332983A CN1314403C (en) | 2002-10-29 | 2002-10-29 | Composition of paeoniflorin and albiflorin and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1413589A true CN1413589A (en) | 2003-04-30 |
| CN1314403C CN1314403C (en) | 2007-05-09 |
Family
ID=4747137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021332983A Expired - Fee Related CN1314403C (en) | 2002-10-29 | 2002-10-29 | Composition of paeoniflorin and albiflorin and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1314403C (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012999A1 (en) * | 2004-08-06 | 2006-02-09 | Indena S.P.A. | The use of paeonia and extracts thereof with growth promoting activity in veterinary medicine and zootechnics |
| CN100336524C (en) * | 2005-07-27 | 2007-09-12 | 南京海陵中药制药工艺技术研究有限公司 | Method for preparing extract product of paeoniflorin |
| CN101156863B (en) * | 2007-09-30 | 2010-09-08 | 广州艾格生物科技有限公司 | A medicine composition for treating cardiac and cerebral vascular disease and its medical usage |
| WO2010133015A1 (en) * | 2009-05-21 | 2010-11-25 | 陈婷 | Pharmaceutical composition for treating depression and preparative method and use thereof |
| CN101940583A (en) * | 2009-07-10 | 2011-01-12 | 张作光 | Antidepressant application of composition of paeoniflorin and albiflorin and preparation method thereof |
| CN1868508B (en) * | 2005-05-25 | 2011-09-14 | 山东绿叶天然药物研究开发有限公司 | Medicine composition, application of the same for preparing medicine to treat and prevent cardiovascular and cerebrovascular disease |
| CN1706397B (en) * | 2005-02-04 | 2011-11-16 | 沈阳药科大学 | Composition of paeoniflorin and peony lactone glycoside with function of increasing leukocyte |
| CN102304159A (en) * | 2011-03-10 | 2012-01-04 | 李伟 | Method for preparing albiflorin and paeoniflorin |
| WO2012061984A1 (en) * | 2010-11-10 | 2012-05-18 | Zhang Zuoguang | Method for preparing albiflorin and paeoniflorin |
| CN101555237B (en) * | 2008-05-09 | 2013-01-09 | 沈阳药科大学 | New monoterpene compounds and preparation method thereof |
| CN102998386A (en) * | 2012-11-22 | 2013-03-27 | 宁波立华制药有限公司 | Method for measuring radix paeoniae alba diglucoside in radix paeoniae alba callus by utilizing high performance liquid chromatography |
| WO2021169273A1 (en) * | 2020-02-27 | 2021-09-02 | 张作光 | Use of albiflorin in treatment of coronavirus pneumonia |
-
2002
- 2002-10-29 CN CNB021332983A patent/CN1314403C/en not_active Expired - Fee Related
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012999A1 (en) * | 2004-08-06 | 2006-02-09 | Indena S.P.A. | The use of paeonia and extracts thereof with growth promoting activity in veterinary medicine and zootechnics |
| CN1706397B (en) * | 2005-02-04 | 2011-11-16 | 沈阳药科大学 | Composition of paeoniflorin and peony lactone glycoside with function of increasing leukocyte |
| CN1868508B (en) * | 2005-05-25 | 2011-09-14 | 山东绿叶天然药物研究开发有限公司 | Medicine composition, application of the same for preparing medicine to treat and prevent cardiovascular and cerebrovascular disease |
| CN100336524C (en) * | 2005-07-27 | 2007-09-12 | 南京海陵中药制药工艺技术研究有限公司 | Method for preparing extract product of paeoniflorin |
| CN101156863B (en) * | 2007-09-30 | 2010-09-08 | 广州艾格生物科技有限公司 | A medicine composition for treating cardiac and cerebral vascular disease and its medical usage |
| CN101555237B (en) * | 2008-05-09 | 2013-01-09 | 沈阳药科大学 | New monoterpene compounds and preparation method thereof |
| WO2010133015A1 (en) * | 2009-05-21 | 2010-11-25 | 陈婷 | Pharmaceutical composition for treating depression and preparative method and use thereof |
| CN101940583A (en) * | 2009-07-10 | 2011-01-12 | 张作光 | Antidepressant application of composition of paeoniflorin and albiflorin and preparation method thereof |
| WO2011003226A1 (en) * | 2009-07-10 | 2011-01-13 | 陈婷 | Pharmaceutical composition for treating depression and preparative method and use thereof |
| CN103180334A (en) * | 2010-11-10 | 2013-06-26 | 张作光 | Method for preparing albiflorin and paeoniflorin |
| WO2012061984A1 (en) * | 2010-11-10 | 2012-05-18 | Zhang Zuoguang | Method for preparing albiflorin and paeoniflorin |
| US9453041B2 (en) | 2010-11-10 | 2016-09-27 | Zuoguang Zhang | Method for preparing albiflorin and paeoniflorin |
| CN102304159A (en) * | 2011-03-10 | 2012-01-04 | 李伟 | Method for preparing albiflorin and paeoniflorin |
| CN102304159B (en) * | 2011-03-10 | 2014-06-25 | 李伟 | Method for preparing albiflorin and paeoniflorin |
| CN102998386A (en) * | 2012-11-22 | 2013-03-27 | 宁波立华制药有限公司 | Method for measuring radix paeoniae alba diglucoside in radix paeoniae alba callus by utilizing high performance liquid chromatography |
| WO2021169273A1 (en) * | 2020-02-27 | 2021-09-02 | 张作光 | Use of albiflorin in treatment of coronavirus pneumonia |
| CN115003310A (en) * | 2020-02-27 | 2022-09-02 | 张作光 | Application of albiflorin in treatment of coronavirus pneumonia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1314403C (en) | 2007-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106692297B (en) | Composition for assisting in reducing blood sugar and preparation method and application thereof | |
| CN1314403C (en) | Composition of paeoniflorin and albiflorin and its preparation method | |
| CN100374120C (en) | Powder of flenabane and its preparation method as well as application in making drugs | |
| CN101711805A (en) | Medicine composition for treating rheumatoid arthritis and preparation thereof | |
| CN102134268B (en) | Method for preparing panax japonicus saponin IVa and application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase | |
| CN1706397B (en) | Composition of paeoniflorin and peony lactone glycoside with function of increasing leukocyte | |
| CN1857473A (en) | Gynostemma pentaphylla saponin composition preparation and its preparing process | |
| CN102078443B (en) | Medicine composition, application and preparation thereof | |
| CN1857388A (en) | Preparation and application of notoginseng stem and leaf total saponin composition | |
| CN1857472A (en) | Ginsenoside composition preparation and its preparing process | |
| CN101204429B (en) | Extractive of total peony ladves flavone-glycoides, preparation method and uses thereof | |
| CN101919901A (en) | Application of total aglycone of gleditsia sinensis and echinocystic acid in preparation of alpha-glucosidase inhibitor drugs | |
| CN101890063B (en) | Chinese medicament for reducing blood sugar and preparation method thereof | |
| CN101564405A (en) | Application of total aglycone of himalayan teasel roots and single-component hederagenin in medicaments preparing Alpha-glucosidase inhibitor | |
| CN101574410A (en) | Effective components of peony leaves as well as preparation method and application thereof | |
| CN100509009C (en) | A Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and ischemic apoplexy, and its preparation method | |
| CN1857441A (en) | Preparation and application of total salvianolic acid composition | |
| CN100431566C (en) | Chinese medicine composition and its prepn process and application | |
| CN100584358C (en) | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method | |
| CN1686200A (en) | Tulip poplar extract, refined extract and its application in medicine preparation | |
| CN100434091C (en) | Fenugreek seed extract and its preparing process and application | |
| CN102247418A (en) | Liver protection effect of panax japonicus total saponin and panax japonicus polysaccharide | |
| CN101269123A (en) | Secondary development novel technique for thirst eliminating capsule for lowering blood sugar | |
| CN1990005A (en) | Cathartic and its preparing method | |
| CN100411653C (en) | Chinese medicine composition for treating diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070509 Termination date: 20141029 |
|
| EXPY | Termination of patent right or utility model |